Cargando…

Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study

Background: Inflammatory bowel diseases in children are characterized by a wide variety of symptoms and often a severe clinical course. In the treatment, we aimed to induce and maintain remission. We focused on assessing the efficacy and safety of the concomitant use of two biologic therapies includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wlazło, Magdalena, Meglicka, Monika, Wiernicka, Anna, Osiecki, Marcin, Kierkuś, Jarosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856313/ https://www.ncbi.nlm.nih.gov/pubmed/36670562 http://dx.doi.org/10.3390/children10010011

Ejemplares similares

Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature
por: Wlazło, Magdalena, et al.
Publicado: (2022)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

Effect of the Crohn’s Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn’s Disease
por: Matuszczyk, Małgorzata, et al.
Publicado: (2022)

Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases
por: Fabiszewska, Sylwia, et al.
Publicado: (2021)

The risk of cardiovascular complications in inflammatory bowel disease
por: Czubkowski, Piotr, et al.
Publicado: (2020)

Inflammatory bowel disease – one entity with many molecular faces
por: Szymańska, Sylwia, et al.
Publicado: (2019)

C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2022)

The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis
por: Szymańska, Edyta, et al.
Publicado: (2020)

Insolation and Disease Severity in Paediatric Inflammatory Bowel Disease—A Multi-Centre Cross-Sectional Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2020)

Genetic Variants of DMBT1 and SFTPD and Disease Severity in Paediatric Inflammatory Bowel Disease—A Polish Population-Based Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Biological markers of disease activity in inflammatory bowel diseases
por: Szymanska, Edyta, et al.
Publicado: (2023)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Subjective Psychophysical Experiences in the Course of Inflammatory Bowel Disease—A Comparative Analysis Based on the Polish Pediatric Crohn’s and Colitis Cohort (POCOCO)
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Usefulness of Colon Assessment by Magnetic Resonance Enterography in Pediatric Patients with Inflammatory Bowel Disease—Retrospective Case Series
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2021)

Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn’s disease – a prospective multicentre trial
por: Matuszczyk, Małgorzata, et al.
Publicado: (2021)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin
por: Szymanska, Edyta, et al.
Publicado: (2021)

Sexual functions in individuals with inflammatory bowel diseases
por: Kotkowicz-Szczur, Marta, et al.
Publicado: (2023)

Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
por: Olbjørn, Christine, et al.
Publicado: (2020)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe
por: Huynh, Lynn, et al.
Publicado: (2022)

Nutritional Therapy in Pediatric Crohn’s Disease—Are We Going to Change the Guidelines?
por: Matuszczyk, Malgorzata, et al.
Publicado: (2021)

Demographic characteristics of children with early clinical manifestation of inflammatory bowel disease
por: Szymańska, Edyta, et al.
Publicado: (2015)

The protocol for a randomised-controlled trial of the evaluation of the tolerance and safety of early enteral nutrition in children after percutaneous endoscopic gastrostomy placement. (protocol version 09.01.2015)
por: Wiernicka, Anna, et al.
Publicado: (2016)

Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population
por: Ostrowski, Jerzy, et al.
Publicado: (2016)

HLA-DQA1*05 Associates with Extensive Ulcerative Colitis at Diagnosis: An Observational Study in Children
por: Nowak, Jan Krzysztof, et al.
Publicado: (2021)

Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
por: McCormack, Matthew D, et al.
Publicado: (2023)

Systematic Review of Cost-Effectiveness of Injury Prevention Interventions in Soccer—Evidence Why Health Agencies Should Address It
por: Grygorowicz, Monika, et al.
Publicado: (2021)

An Overview of Tools to Score Severity in Pediatric Inflammatory Bowel Disease
por: Shaoul, Ron, et al.
Publicado: (2021)

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease
por: Szymanska, Edyta, et al.
Publicado: (2015)

Redefining the Practical Utility of Blood Transcriptome Biomarkers in Inflammatory Bowel Diseases
por: Ostrowski, Jerzy, et al.
Publicado: (2019)

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
por: Golhen, Klervi, et al.
Publicado: (2022)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Sherlock, Mary E, et al.
Publicado: (2020)

Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review
por: Damião, Adérson Omar Mourão Cintra, et al.
Publicado: (2019)

Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
por: Kapoor, Akshay, et al.
Publicado: (2021)

Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
por: Torun, Anna, et al.
Publicado: (2021)

Biologic Therapies for Moderate to Severe Asthma in the Pediatric Population: A Practice Update
por: Tolomeo, Concettina
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gm0d8pdui9f30q8ukgfqcodias